Full Press Release Details
Accessibility: Skip TopNav
Summit Corporation PLC : Directorate change
March 01, 2013 02:00 ET
Summit Therapeutics plc
Summit Therapeutics plc
Summit Corporation plc
('Summit' or 'the Company')
Oxford, UK, 1 March 2013 - Summit (AIM: SUMM), a drug discovery and development company advancing therapies for Duchenne Muscular Dystrophy and C. difficile infections, today announces that Professor Stephen Davies has stepped down from the Board of Directors, effective from 28 February 2013, to concentrate on other projects.
Dr Barry Price, Chairman of Summit commented, "On behalf of the Board, I would sincerely like to thank Steve for his important contribution towards the development of Summit during his many years of service and we wish him every success for the future."
Summit is an Oxford, UK based drug discovery and development Company targeting high-value areas of unmet medical need including Duchenne Muscular Dystrophy and C. difficile infection. Summit is listed on the AIM market of the London Stock Exchange and trades under the ticker symbol SUMM. Further information is available at www.summitplc.com.
For more information, please contact:
| Summit Glyn Edwards / Richard Pye | Tel: +44 (0)1235 443 951 |
| Nomura Code Securities (Nominated Adviser and Joint broker) Chris Collins / Jonathan Senior / Giles Balleny | Tel: +44 (0)20 7776 1200 |
| Hybridan LLP (Joint broker) Claire Louise Noyce / Deepak Reddy | Tel: +44 (0)207 947 4350 |
| Peckwater PR (Financial public relations, UK) Tarquin Edwards | Tel: +44 (0)7879 458 364 tarquin.edwards@peckwaterpr.co.uk |
| MacDougall Biomedical Communications (US media contact) Michelle Avery | Tel: +1 781-235-3060 |
Forward Looking Statements
This document contains "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as "anticipates", "intends", "plans", "seeks", "believes", "estimates", "expects" and similar references to future periods, or by the inclusion of forecasts or projections. Forward-looking statements are based on the Company's current expectations and assumptions regarding our business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. The Company's actual results may differ materially from those contemplated by the forward-looking statements. The Company cautions you therefore that you should not rely on any of these forward-looking statements as statements of historical fact or as guarantees or assurances of future performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements and regional, national, global political, economic, business, competitive, market and regulatory conditions.